Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Wave Life Sciences Ltd. (WVE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Investor presentation, Quarterly results |
| 05/03/2023 |
8-K
| Investor presentation, Quarterly results |
| 03/22/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/03/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Investor presentation, Quarterly results |
| 03/04/2021 |
8-K
| Quarterly results |
| 11/09/2020 |
8-K
| Quarterly results |
| 08/10/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 03/02/2020 |
8-K
| Quarterly results |
| 11/05/2019 |
8-K
| Investor presentation, Quarterly results |
| 07/29/2019 |
8-K
| Quarterly results |
| 05/10/2019 |
8-K
| Investor presentation, Quarterly results |
| 03/01/2019 |
8-K
| Quarterly results |
| 11/09/2018 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"FORM 8-K",
"Wave Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass., November 9, 2018 - Wave Life Sciences Ltd. , a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the third quarter ended September 30, 2018 and provided a business update. “During the third quarter we maintained strong momentum in advancing our three clinical programs and expect to announce our company's first clinical readout later this year when we share topline safety results from the Phase 1 trial for WVE-210201, our investigational exon 51 skipping candidate for the treatment of Duchenne muscular dystrophy,” said Paul Bolno, MD, MBA, President and Chief Executiv...",
"Corporate Presentation of Wave Life Sciences Ltd." |
|
| 08/09/2018 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : August 9, 2018 WAVE LIFE SCIENCES LTD. Singapore 001-37627 Not Applicable 7 Straits View #12-00 Marina One East Tower Singapore 018936 Registrant's telephone number, including area code: +65 6236 3388 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) 	...",
"Wave Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass, August 9, 2018 - Wave Life Sciences Ltd. , a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the second quarter ended June 30, 2018 and provided a business update. “We continue to advance our programs for the treatment of Duchenne muscular dystrophy with preparations underway for our global, pivotal trial of investigational WVE-210201 for boys amenable to exon 51 skipping. Recently presented preclinical data demonstrating that our stereopure oligonucleotides can restore up to 90% of natural dystrophin in an animal model underscore the significant potential of our p...",
"Corporate Presentation of Wave Life Sciences Ltd." |
|
| 05/09/2018 |
8-K
| Quarterly results |
| 03/12/2018 |
8-K
| Investor presentation, Quarterly results |
| 11/09/2017 |
8-K
| Quarterly results |
| 08/09/2017 |
8-K
| Quarterly results |
| 05/10/2017 |
8-K
| Form 8-K - Current report |
| 03/16/2017 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 03/30/2016 |
8-K
| Quarterly results |
|
|